Psoriatic Arthritis Clinical Trial
Official title:
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic arthritis (PsA) is an inflammatory arthritis with substantial variation in clinical features. We propose a multicenter collaborative approach to better understand the phenotypes and current management of PsA in the United States.The central goal of this proposal is to obtain the data necessary to design a pragmatic trial in PsA.
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that can be associated with devastating outcomes including irreversible joint damage. The management of a patient with PsA is extremely challenging due to the high degree of phenotypic heterogeneity. The ultimate goal of this proposal is to prepare pragmatic trials in PsA trials that will encompass all relevant subgroups of patients. The aims of this study specifically focus on responses to biologic therapy among patients with PsA and determining the optimal set of outcome measures for PsA trials. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04152759 -
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Completed |
NCT01925768 -
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT01892436 -
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT01212770 -
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Completed |
NCT01212757 -
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT03953378 -
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
|
||
| Recruiting |
NCT02572700 -
Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
|
||
| Completed |
NCT02556034 -
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT02188654 -
Metformin in Psoriatic Arthritis
|
N/A | |
| Completed |
NCT01392326 -
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
|
Phase 3 | |
| Completed |
NCT02164214 -
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
|
Phase 3 | |
| Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
| Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
| Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 | |
| Completed |
NCT00659412 -
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
|
Phase 2 | |
| Completed |
NCT00946686 -
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
|
Phase 1 | |
| Not yet recruiting |
NCT06059430 -
Cohort Project of Patients With Inflammatory Rheumatism
|